vs

Side-by-side financial comparison of BigBear.ai Holdings, Inc. (BBAI) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.

BigBear.ai Holdings, Inc. is the larger business by last-quarter revenue ($27.3M vs $19.1M, roughly 1.4× NewAmsterdam Pharma Co N.V.). On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -37.7%). BigBear.ai Holdings, Inc. produced more free cash flow last quarter ($-22.1M vs $-37.8M).

BigBear.ai Holdings, Inc. develops and delivers artificial intelligence-powered decision support and analytics solutions. Its core offerings cover predictive analytics, supply chain optimization, and operational intelligence platforms, serving key segments including national defense, intelligence agencies, and commercial enterprise clients primarily across North America, helping customers improve operational efficiency and mitigate risks.

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

BBAI vs NAMS — Head-to-Head

Bigger by revenue
BBAI
BBAI
1.4× larger
BBAI
$27.3M
$19.1M
NAMS
Growing faster (revenue YoY)
NAMS
NAMS
+777.8% gap
NAMS
740.1%
-37.7%
BBAI
More free cash flow
BBAI
BBAI
$15.7M more FCF
BBAI
$-22.1M
$-37.8M
NAMS

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
BBAI
BBAI
NAMS
NAMS
Revenue
$27.3M
$19.1M
Net Profit
$-17.4M
Gross Margin
20.3%
Operating Margin
-295.0%
-186.1%
Net Margin
-90.7%
Revenue YoY
-37.7%
740.1%
Net Profit YoY
55.5%
EPS (diluted)
$0.17
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBAI
BBAI
NAMS
NAMS
Q4 25
$27.3M
Q3 25
$33.1M
Q2 25
$32.5M
$19.1M
Q1 25
$34.8M
Q4 24
$43.8M
$12.8M
Q3 24
$41.5M
$29.1M
Q2 24
$39.8M
Q1 24
$33.1M
Net Profit
BBAI
BBAI
NAMS
NAMS
Q4 25
Q3 25
$2.5M
Q2 25
$-228.6M
$-17.4M
Q1 25
$-62.0M
Q4 24
$-92.2M
Q3 24
$-15.1M
$-16.6M
Q2 24
$-14.4M
Q1 24
$-127.8M
Gross Margin
BBAI
BBAI
NAMS
NAMS
Q4 25
20.3%
Q3 25
22.4%
Q2 25
25.0%
Q1 25
21.3%
Q4 24
37.4%
Q3 24
25.9%
Q2 24
27.8%
Q1 24
21.1%
Operating Margin
BBAI
BBAI
NAMS
NAMS
Q4 25
-295.0%
Q3 25
-66.0%
Q2 25
-278.1%
-186.1%
Q1 25
-61.0%
Q4 24
-18.6%
-338.5%
Q3 24
-25.4%
-85.9%
Q2 24
-41.9%
Q1 24
-296.1%
Net Margin
BBAI
BBAI
NAMS
NAMS
Q4 25
Q3 25
7.6%
Q2 25
-704.0%
-90.7%
Q1 25
-178.3%
Q4 24
-721.7%
Q3 24
-36.5%
-57.2%
Q2 24
-36.3%
Q1 24
-385.8%
EPS (diluted)
BBAI
BBAI
NAMS
NAMS
Q4 25
$0.17
Q3 25
$-0.03
Q2 25
$-0.71
$-0.15
Q1 25
$-0.25
Q4 24
$-0.47
$-0.91
Q3 24
$-0.06
$-0.18
Q2 24
$-0.06
Q1 24
$-0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBAI
BBAI
NAMS
NAMS
Cash + ST InvestmentsLiquidity on hand
$87.1M
$739.2M
Total DebtLower is stronger
$107.0M
Stockholders' EquityBook value
$611.9M
$778.5M
Total Assets
$894.5M
$815.1M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBAI
BBAI
NAMS
NAMS
Q4 25
$87.1M
Q3 25
$456.6M
Q2 25
$390.8M
$739.2M
Q1 25
$107.6M
Q4 24
$50.1M
$834.2M
Q3 24
$65.6M
$422.7M
Q2 24
$72.3M
Q1 24
$81.4M
Total Debt
BBAI
BBAI
NAMS
NAMS
Q4 25
$107.0M
Q3 25
$104.9M
Q2 25
$103.0M
Q1 25
$101.4M
Q4 24
$136.2M
Q3 24
$195.7M
Q2 24
$195.7M
Q1 24
$195.6M
Stockholders' Equity
BBAI
BBAI
NAMS
NAMS
Q4 25
$611.9M
Q3 25
$610.0M
Q2 25
$266.6M
$778.5M
Q1 25
$197.8M
Q4 24
$-3.7M
$757.5M
Q3 24
$127.5M
$378.9M
Q2 24
$134.7M
Q1 24
$143.2M
Total Assets
BBAI
BBAI
NAMS
NAMS
Q4 25
$894.5M
Q3 25
$919.8M
Q2 25
$599.4M
$815.1M
Q1 25
$396.3M
Q4 24
$343.8M
$864.6M
Q3 24
$354.1M
$439.2M
Q2 24
$360.9M
Q1 24
$377.6M
Debt / Equity
BBAI
BBAI
NAMS
NAMS
Q4 25
0.17×
Q3 25
0.17×
Q2 25
0.39×
Q1 25
0.51×
Q4 24
Q3 24
1.54×
Q2 24
1.45×
Q1 24
1.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBAI
BBAI
NAMS
NAMS
Operating Cash FlowLast quarter
$-21.8M
$-37.7M
Free Cash FlowOCF − Capex
$-22.1M
$-37.8M
FCF MarginFCF / Revenue
-80.9%
-197.2%
Capex IntensityCapex / Revenue
0.9%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-42.5M
$-119.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBAI
BBAI
NAMS
NAMS
Q4 25
$-21.8M
Q3 25
$-9.6M
Q2 25
$-3.9M
$-37.7M
Q1 25
$-6.7M
Q4 24
$-14.8M
$-37.5M
Q3 24
$-1.9M
$-12.5M
Q2 24
$-7.1M
Q1 24
$-14.4M
Free Cash Flow
BBAI
BBAI
NAMS
NAMS
Q4 25
$-22.1M
Q3 25
$-9.8M
Q2 25
$-3.9M
$-37.8M
Q1 25
$-6.7M
Q4 24
$-15.0M
$-37.5M
Q3 24
$-2.0M
$-12.6M
Q2 24
$-7.2M
Q1 24
$-14.4M
FCF Margin
BBAI
BBAI
NAMS
NAMS
Q4 25
-80.9%
Q3 25
-29.5%
Q2 25
-11.9%
-197.2%
Q1 25
-19.4%
Q4 24
-34.2%
-293.5%
Q3 24
-4.9%
-43.2%
Q2 24
-18.1%
Q1 24
-43.5%
Capex Intensity
BBAI
BBAI
NAMS
NAMS
Q4 25
0.9%
Q3 25
0.6%
Q2 25
0.0%
0.5%
Q1 25
0.2%
Q4 24
0.4%
0.0%
Q3 24
0.3%
0.3%
Q2 24
0.3%
Q1 24
0.1%
Cash Conversion
BBAI
BBAI
NAMS
NAMS
Q4 25
Q3 25
-3.80×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons